Immunohistochemical detection of LMP2A and double immunohistochemical staining for LMP2A and CK7.

<p><b>A</b>) Ductal breast carcinoma with a high number of LMP2A positive cells. Positive signal for LMP2A is restricted to the cytoplasm and membrane of tumor epithelial cells (1000X). <b>B</b>) LMP2A negative ductal carcinoma tissue (1000X). <b>C</b>) Ductal breast carcinoma. Positive double signal for LMP2A (brown signal, dotted arrow) and CK7 (blue signal, full arrow) restricted to the cytoplasm and membrane of the same tumor epithelial cells (1000X).</p

EBV gene latency programs.

<p>N.D.: not determined; BL: Burkitt lymphoma; PEL: Primary effusion lymphoma; PTLD: post-transplant lymphoproliferative disorders; GC: gastric carcinoma; HL: Hodgkin lymphoma; NPC: nasopharyngeal carcinoma; IM: infectious mononucleosis.</p><p>*: not determined due to unavailability of commercial antibodies for formalin fixed, paraffin embedded tissue sections.</p

Immunohistochemical detection of EBNA1 (clones 1H4 and 2B4).

<p><b>A</b>) Ductal breast carcinoma neoplastic nuclei show positive staining with EBNA1 (clone 1H4) monoclonal antibody, (black arrows), but no infiltrating lymphocyte gave positive signal (400X). <b>B</b>) EBNA1 (clone 1H4) negative ductal carcinoma tissue (400X). <b>C</b>) EBNA1 (clone 2B4) positive signal in nuclei of neoplastic breast cells (400X). <b>D</b>) EBNA1 (clone 2B4) negative ductal carcinoma tissue (400X).</p

Immunohistochemical controls for LMP1 and EBERs RNA <i>in situ</i> hybridization.

<p><b>A</b>) HL case: LMP1 positive staining in the membrane of Reed Stenberg cells and HL mononuclear cell (400X). <b>B</b>) LMP1 negative ductal breast carcinoma (400X). <b>C</b>) EBERs RNA positive staining in HL Reed Stenberg cells (400X). <b>D</b>) EBERs RNA negative ductal breast carcinoma (400X).</p

Apoptosis markers in serum samples from CHC patients vs healthy subjects.

<p>*p<0.05; ** p<0.001; ***p<0.0001;·^# trend of association p<0.07.</p

Clinical, virological and histological features of adult CHC patients.

<p>F: female, M: male.</p>*<p>Subtype not determined Risk factor for HCV infection: T: transfusion, DA: drug abuse, OE: occupational exposure.</p><p>ALT: alanine aminotransferase; AST: aspartate aminotransferase. Normal ALT and AST levels were ≤40 and ≤42 IU/L, respectively when test was done at 37°C.</p>#<p>Fibrosis stages according METAVIR.</p

Serum markers related to liver damage in CHC patients.

<p>a) fibrosis, b) hepatitis and c) steatosis severity. Fibrosis stages according METAVIR. Significant fibrosis (F≥2) and advanced fibrosis (F≥3). * p<0.05;·^# trend of association p<0.08.</p

Clinical, virological and histological features of pediatric CHC patients.

<p>F: female, M: male. ND: not determined Bx I, Bx II, Bx III denote: multiple liver biopsies. Risk factor for HCV infection: T: transfusion, V: vertical transmission.</p><p>ALT: alanine aminotransferase; AST: aspartate aminotransferase. Normal ALT and AST levels were ≤32 and ≤48 IU/L, respectively when test was done at 37°C.</p>#<p>Fibrosis stages according METAVIR.</p

Diagnostic accuracy of M30 for steatosis severity in pediatric CHC patients.

*<p>U/L.</p

Diagnostic accuracy of sFas for significant and advance fibrosis in CHC patients.

*<p>pg/ml.</p